influenza vaccine A (H5N8)

The **influenza vaccine A (H5N8)** is an inactivated, fragmented (split-virion), monovalent vaccine candidate developed by the **Instituto Butantan** for pandemic preparedness. It specifically targets the avian influenza A virus subtype H5N8, which has been identified as a significant potential threat for human transmission. The vaccine is formulated with the **IB160 adjuvant** (an oil-in-water emulsion) to enhance immunogenicity, particularly to overcome the poor immune response typically elicited by avian influenza antigens. Its mechanism of action involves presenting viral proteins to the immune system to stimulate the production of neutralizing antibodies against the **hemagglutinin (HA)** protein. This prevents viral attachment and entry into host cells, thereby providing protection against infection and severe disease in the event of an outbreak or pandemic.

Other names

monovalent influenza vaccine A (H5N8)A (H5N8) inactivated vaccinesplit-virion A (H5N8) vaccineinactivated fragmented adjuvanted A (H5N8) vaccine